Principal Financial Group
KZR

Principal Financial Group’s Kezar Life Sciences KZR Stock Holding History

Principal Financial Group’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,197
Closed -$19.8K – 2413
2024
Q1 		$19.8K Sell
2,197
-514
-19% -$4.68K ﹤0.01% 2409
2023
Q4 		$25.7K Sell
2,711
-190
-7% -$1.67K ﹤0.01% 2377
2023
Q3 		$34.5K Buy
2,901
+237
+9% +$4.2K ﹤0.01% 2374
2023
Q2 		$65.3K Buy
2,664
+976
+58% +$25.4K ﹤0.01% 2340
2023
Q1 		$52.8K Buy
1,688
+173
+11% +$10K ﹤0.01% 2372
2022
Q4 		$107K Buy
1,515
+405
+36% +$30K ﹤0.01% 2285
2022
Q3 		$96K Buy
+1,110
New +$108K ﹤0.01% 2339

Other funds holding KZR

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Principal Financial Group's KZR Position: Q2 2024 in Review

Principal Financial Group sold out of Kezar Life Sciences (KZR) in Q2 2024, closing a stake of 2,197 shares — an estimated $19.8K sold.

Principal Financial Group first reported a position in KZR in Q3 2022 and held it in 7 quarters. The position peaked at $107K in Q4 2022. 81 funds tracked by Wall St. Rank hold KZR as of Q2 2024.

  • Principal Financial Group reported no remaining Kezar Life Sciences position as of Q2 2024 after selling out during the quarter.
  • Principal Financial Group sold 2,197 Kezar Life Sciences shares in Q2 2024, an estimated $19.8K.
  • Principal Financial Group first reported a position in Kezar Life Sciences in Q3 2022 and held it in 7 quarters.
  • Principal Financial Group's Kezar Life Sciences position peaked at $107K in Q4 2022.
  • 81 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q2 2024.

Based on Principal Financial Group's 13F filing for Q2 2024, filed 29 Jul 2024.